Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 1
2021 4
2022 2
2023 4
2024 4
2025 5
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.
Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, Moulec SL, Besse B, Loriot Y, Larroquette M, Soubeyran I, Toulmonde M, Roubaud G, Pernot S, Cabart M, Chomy F, Lefevre C, Bourcier K, Kind M, Giglioli I, Sautès-Fridman C, Velasco V, Courgeon F, Oflazoglu E, Savina A, Marabelle A, Soria JC, Bellera C, Sofeu C, Bessede A, Fridman WH, Loarer FL, Italiano A. Vanhersecke L, et al. Among authors: larroquette m. Nat Cancer. 2021 Aug;2(8):794-802. doi: 10.1038/s43018-021-00232-6. Epub 2021 Aug 12. Nat Cancer. 2021. PMID: 35118423 Free PMC article.
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Larroquette M, Guegan JP, Besse B, Cousin S, Brunet M, Le Moulec S, Le Loarer F, Rey C, Soria JC, Barlesi F, Bessede A, Scoazec JY, Soubeyran I, Italiano A. Larroquette M, et al. J Immunother Cancer. 2022 May;10(5):e003890. doi: 10.1136/jitc-2021-003890. J Immunother Cancer. 2022. PMID: 35618288 Free PMC article.
Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile.
Burban A, Tessier C, Larroquette M, Guyon J, Lubiato C, Pinglaut M, Toujas M, Galvis J, Dartigues B, Georget E, Luchman HA, Weiss S, Cappellen D, Nicot N, Klink B, Nikolski M, Brisson L, Mathivet T, Bikfalvi A, Daubon T, Sharanek A. Burban A, et al. Among authors: larroquette m. EMBO Mol Med. 2025 Mar;17(3):469-503. doi: 10.1038/s44321-025-00195-6. Epub 2025 Feb 3. EMBO Mol Med. 2025. PMID: 39901019 Free PMC article.
Which place for avelumab in the management of urothelial carcinoma?
Larroquette M, Gross-Goupil M, Daste A, Robert G, Ravaud A, Domblides C. Larroquette M, et al. Expert Opin Biol Ther. 2019 Sep;19(9):863-870. doi: 10.1080/14712598.2019.1637412. Epub 2019 Jul 9. Expert Opin Biol Ther. 2019. PMID: 31286802 Review.
Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real-life national setting over a decade.
Ducrot C, Dinart D, Reich M, Piffoux M, Bonneau M, Larroquette M, Nannini S, Berchoud J, Bellio H, Cherrier G, Narciso B, Le Cesne A, Bompas E, Gantzer J, Valentin T, Anract P, de Percin S, Boudou-Rouquette P, de Pinieux G, Gouin F, Brahmi M, Bellera C, Toulmonde M. Ducrot C, et al. Among authors: larroquette m. Int J Cancer. 2025 Dec 1;157(11):2325-2333. doi: 10.1002/ijc.70023. Epub 2025 Jul 24. Int J Cancer. 2025. PMID: 40705468
21 results